



kathryn ardizzone <kathrynardizzonekei@gmail.com>

Questions Re: Prospective Grant of an Exclusive Patent License: Genetically-Modified Lymphocytes for Cancer Therapy

Burke, Andy (NIH/NCI) [E] <andy.burke@nih.gov>

Wed, Sep 11, 2019 at 4:45 PM

To: kathryn ardizzone <kathrynardizzonekei@gmail.com>

Cc: Luis Gil Abinader <luis.gil.abinader@keionline.org>, James Love <james.love@keionline.org>

Dear Ms. Ardizzone,

Answers to your questions are provided below.

Regards,

Andy

From: kathryn ardizzone <kathrynardizzonekei@gmail.com>

Sent: Wednesday, September 11, 2019 2:29 PM

To: Burke, Andy (NIH/NCI) [E] <andy.burke@nih.gov>

Cc: Luis Gil Abinader <luis.gil.abinader@keionline.org>; James Love <james.love@keionline.org>

Subject: Re: Questions Re: Prospective Grant of an Exclusive Patent License: Genetically-Modified Lymphocytes for Cancer Therapy

Dear Dr. Burke:

Thank you for your response.

Given the lack of publicly-available data about the company (no website, no registration in NY, no officers or contact information for those officers listed in Delaware corporate records), how do you propose that KEI request this information directly from the company? **Answer: The company's mailing address is publicly-available, as is a phone number. Please see, for example, <https://start.cortera.com/company/research/l6o5lxm2r/intima-bioscience-inc/>.**

Also, please clarify why you are unable to release this information. **Answer: Please see 37 CFR 404.14**

[Quoted text hidden]

[Quoted text hidden]